BELLUS Health Inc.
BLU · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.33 | 0.93 | -0.36 | 0.65 |
| FCF Yield | -0.40% | -0.55% | -3.52% | -3.74% |
| EV / EBITDA | -93.82 | -179.99 | -33.08 | -45.25 |
| Quality | ||||
| ROIC | -5.72% | -3.53% | -7.50% | -5.53% |
| Gross Margin | 2.51% | 4.98% | -47,701,843.43% | -23,009,535.58% |
| Cash Conversion Ratio | 0.41 | 1.27 | 1.08 | 1.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 5,731.76% | 4,564.37% | -0.00% | 2.17% |
| Free Cash Flow Growth | 30.68% | -4.32% | 9.39% | -55.54% |
| Safety | ||||
| Net Debt / EBITDA | 3.86 | 7.86 | 3.37 | 4.51 |
| Interest Coverage | 0.00 | 0.00 | -1,386.20 | -942.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 723,209,186.50 | 0.00 | 0.00 |
| Cash Conversion Cycle | 77.56 | 89.74 | 61,259.41 | 36,967.06 |